Postoperative Ileus: Duration and Severity Assessment With the SmartPill®
NCT ID: NCT02329912
Last Updated: 2015-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
55 participants
INTERVENTIONAL
2014-12-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Until now there is no evidence based therapy of manifest POI because of missing valid surrogate markers demonstrating the severity and resolution of POI.
A novel tool to examine gastrointestinal function is the SmartPill®. By measuring pH value, temperature and intraluminal pressure the capsule is able to analyse gastric emptying, small bowel transit, large bowel transit and peristaltic activity.
Unfortunately the use of the SmartPill® is not allowed in the first three months after abdominal surgery. Therefore a trial is needed to investigate the behaviour of the SmartPill® during its passage through the human gastrointestinal tract immediately after surgery.
The primary endpoint is
\- to investigate the safety of the SmartPill® in patients after abdominal surgery.
The secondary endpoints are:
* is the SmartPill® able to detect the gastrointestinal transit and the peristaltic activity followed by abdominal surgery compared with patients which underwent thoracic/vascular surgery.
* is it possible to correlate the measured parameters (delayed gastrointestinal transit, lack of peristalsis) with the clinical signs of POI (nausea, vomiting, prolonged duration until first postoperative defecation).
* is the detected peristaltic activity influenced by intravenous applicated prokinetic drugs
* is the detected peristaltic activity influenced by physiotherapy
Using those endpoints the investigators hope to demonstrate the safety of the SmartPill® after abdominal surgery, to evaluate its ability to analyse severity and length of POI and to examine whether the used prokinetic drugs and postoperative mobilization are able to influence peristaltic activity.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Until now there is no evidence based therapy of manifest POI. Instead, the quality of the existing clinical trials are just of low or moderate quality. The main reason for this is the lack of a valid surrogate marker to define the end of POI: Some trials used first flatus or first defecation as a marker for purposeful peristalsis and resolution of POI, others used the ability to consume solid food again or auscultation of bowel sounds. However it remains questionable whether these parameters are really able to demonstrate the severity or the end of POI.
Therefore POI research needs a reliable, patient and investigator independent parameter that is able to determine resolution of POI to improve the quality of future clinical trials.
A novel tool to examine gastrointestinal function is the SmartPill®. The capsule is able to measure pH value, temperature and intraluminal pressure after oral application, the data is sent to a transmitter located near the patient. Using those values, it is possible to analyse gastric emptying, length of small bowel, large bowel or whole gut passage and the smooth muscle contractility/peristalsis of the whole gastrointestinal tract. Therefore the SmartPill® would be an ideal, patient and investigator independent tool to investigate gastrointestinal function and transit time after visceral surgery.
Unfortunately the use of the SmartPill® is not allowed in the first three months after abdominal surgery. Therefore a trial is needed to investigate the behaviour of the SmartPill® during its passage through the human gastrointestinal tract immediately after surgery.
The primary endpoint is
\- to investigate the safety of the SmartPill® in patients after abdominal surgery.
The secondary endpoints are:
* is the SmartPill® able to detect the gastrointestinal transit and the peristaltic activity followed by abdominal surgery compared with patients which underwent thoracic/vascular surgery.
* is it possible to correlate the measured parameters (delayed gastrointestinal transit, lack of peristalsis) with the clinical signs of POI (nausea, vomiting, prolonged duration until first postoperative defecation).
* is the detected peristaltic activity influenced by intravenous applicated prokinetic drugs
* is the detected peristaltic activity influenced by physiotherapy
Using those endpoints the investigators hope to demonstrate the safety of the SmartPill® after abdominal surgery, to evaluate its ability to analyse severity and lenght of POI and to examine whether the used prokinetic drugs and postoperative mobilization are able to influence peristaltic activity.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients after abdominal surgery
SmartPill application after abdominal surgery
SmartPill
Application of the SmartPill at the end of surgery
Patients after extraabdominal surgery
SmartPill after extraabdominal surgery
SmartPill
Application of the SmartPill at the end of surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SmartPill
Application of the SmartPill at the end of surgery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 18 years
* written informed consent
* ASA score I - III
* negative serum pregnancy test
Exclusion Criteria
* existing or planned pregnancy
* emergency surgery
* NSAID (non steroidal antiinflammatory drugs) induced enteropathy
* BMI \> 40
* dysphagia
* medical history of gastric bezoars
* medication with proton pump inhibitor, H2-blockers or antacids
* necessity of an MRI in the first two weeks after the operation
* ASA score IV or higher
* gastro-esophageal reflux ("Savary and Miller" III or IV)
* anastomosis between esophagus and jejunum
* fistula or stenosis of the GI tract which is not treated by the operation
* active Crohn´s disease
* Diverticulitis/severe diverticulosis, which is not treated during the operation
* the following operations: all kind of organ transplantations, extended liver resections (extended right or left hemihepatectomy), very low rectum resection with or without a loop ileostoma, small bowel resection with end-to-end anastomosis, near total gastrectomy, transhiatal extended gastrectomy
* patients undergoing abdominal surgery with an increased bleeding propensity (INR \> 2, thrombocytes \< 50 G/l...)
* perioperative treatment with ciclosporin, tacrolimus, sirolimus, everolimus, methotrexate, Decortin \> 15 mg/d, bevazicumab
* no complete inspection for adhesions, fistulas etc. was possible during the operation
* unexpected events during the operation (major bleeding with transfusion of 2 or more erythrocyte concentrates, hazardously anastomosis) mentioned by the surgeon
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Bonn
OTHER
University Hospital, Bonn
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. med. Tim Vilz
Deputy Head of the Surgical Study Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tim O. Vilz, MD
Role: STUDY_DIRECTOR
Department of Surgery, University of Bonn
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Surgery, University of Bonn
Bonn, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Tran K, Brun R, Kuo B. Evaluation of regional and whole gut motility using the wireless motility capsule: relevance in clinical practice. Therap Adv Gastroenterol. 2012 Jul;5(4):249-60. doi: 10.1177/1756283X12437874.
Storch I, Barkin JS. Contraindications to capsule endoscopy: do any still exist? Gastrointest Endosc Clin N Am. 2006 Apr;16(2):329-36. doi: 10.1016/j.giec.2006.01.017.
Vilz TO, Pantelis D, Lingohr P, Fimmers R, Esmann A, Randau T, Kalff JC, Coenen M, Wehner S. SmartPill(R) as an objective parameter for determination of severity and duration of postoperative ileus: study protocol of a prospective, two-arm, open-label trial (the PIDuSA study). BMJ Open. 2016 Jul 8;6(7):e011014. doi: 10.1136/bmjopen-2015-011014.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
O-112.0055
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
CHI-201202
Identifier Type: -
Identifier Source: org_study_id